2008 Clinical Practice Guidelines - Canadian Diabetes Association

Obstet Gynecol. 1995;172:151-155.
56. Egger M, Davey Smith G, Stettler C, et al. Risk of adverse
effects of intensified treatment in insulin-dependent diabetes
mellitus: a meta-analysis. Diabet Med. 1997;14:919-928.
57. Rosenn BM, Miodovnik M, Khoury JC, et al. Deficient counterregulation:
a possible risk factor for excessive fetal growth
in IDDM pregnancies. Diabetes Care. 1997;20:872-874.
58. Silverman BL, Rizzo TA, Cho NH, et al. Long-term effects of
the intrauterine environment. The Northwestern University
Diabetes in Pregnancy Center. Diabetes Care. 1998;21(suppl 2):
B142-B149.
59. Ornoy A. Growth and neurodevelopmental outcome of children
born to mothers with pregestational and gestational diabetes.
Pediatr Endocrinol Rev. 2005;3:104-113.
60. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition
principles and recommendations for the treatment and prevention
of diabetes and related complications. Diabetes Care.
2002;25:148-198.
61. Jovanovic L. Medical nutritional therapy in pregnant women
with pregestational diabetes mellitus. J Matern Fetal Med.
2000;9:21-28.
62. Knopp RH, Magee MS, Raisys V, et al. Metabolic effects of
hypocaloric diets in management of gestational diabetes.
Diabetes. 1991;40(suppl 2):165-171.
63. Sternfeld B, Quesenberry CP Jr, Eskenazi B, et al. Exercise
during pregnancy and pregnancy outcome. Med Sci Sports Exerc.
1995;27:634-640.
64. Jovanovic L, Druzin M, Peterson CM. Effect of euglycemia on
the outcome of pregnancy in insulin-dependent diabetic
women as compared with normal control subjects. Am J Med.
1981;71:921-927.
65. Nachum Z, Ben-Shlomo I,Weiner E, et al. Twice daily versus
four times daily insulin dose regimens for diabetes in pregnancy:
randomised controlled trial. BMJ. 1999;319:1223-1227.
66. Chauhan SP, Perry KG Jr, McLaughlin BN, et al. Diabetic
ketoacidosis complicating pregnancy. J Perinatol. 1996;16:173-
175.
67. Boskovic R, Feig DS, Derewlany L, et al. Transfer of insulin
lispro across the human placenta: in vitro perfusion studies.
Diabetes Care. 2003;26:1390-1394.
68. Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy
in pregnancies complicated by type 1 diabetes mellitus.
Diabetes Res Clin Pract. 2002;58:115-121.
69. Wyatt JW, Frias JL, Hoyme HE, et al; IONS study group.
Congenital anomaly rate in offspring of mothers with diabetes
treated with insulin lispro during pregnancy. Diabet Med.
2005;22:803-807.
70. Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart
Pregnancy Study Group. Maternal glycemic control and hypoglycemia
in type 1 diabetic pregnancy: a randomized trial of
insulin aspart versus human insulin in 322 pregnant women.
Diabetes Care. 2007;30:771-776.
71. Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic
control and perinatal outcome in women with gestational dia-
betes treated with regular or lispro insulin: comparison with
non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol.
2003;111:19-24.
72. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an
insulin analog, insulin aspart, and regular human insulin with
no insulin in gestational diabetes mellitus. Diabetes Care. 2003;
26:183-186.
73. Plank J, Siebenhofer A, Berghold A, et al. Systematic review
and meta-analysis of short-acting insulin analogues in patients
with diabetes mellitus. Arch Intern Med. 2005;165:1337-1344.
74. Gallen IW, Jaap A, Roland JM, et al. Survey of glargine use in
115 pregnant women with type 1 diabetes. Diabet Med. 2008;
25:165-169.
75. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of
receptor binding and metabolic and mitogenic potencies of
insulin analogs designed for clinical use. Diabetes. 2000;49:
999-1005.
76. Gutzin SJ, Kozer E, Magee LA, et al.The safety of oral hypoglycemic
agents in the first trimester of pregnancy: a metaanalysis.
Can J Clin Pharmacol. 2003;10:179-183.
77. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic
agents in 118 diabetic pregnancies. Diabet Med. 2000;
17:507-511.
78. Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-year
retrospective analysis of pregnancy outcome in pregestational
type 2 diabetes: comparison of insulin and oral glucose-lowering
agents. Diabet Med. 2007;24:253-258.
79. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy
throughout pregnancy reduces the development of gestational
diabetes in women with polycystic ovary syndrome. Fertil
Steril. 2002;77:520-525.
80. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight,
and motor-social development during the first 18 months of
life in 126 infants born to 109 mothers with polycystic ovary
syndrome who conceived on and continued metformin
through pregnancy. Hum Reprod. 2004;19:1323-1330.
81. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social
development in breast- and formula-fed infants of metformintreated
women with polycystic ovary syndrome. J Pediatr.
2006;148:628-632.
82. Mayer-Davis EJ, Rifas-Shiman SL, Zhou L, et al. Breast-feeding
and risk for childhood obesity: does maternal diabetes or
obesity status matter? Diabetes Care. 2006;29:2231-2237.
83. Gardiner SJ, Kirkpatrick CM, Begg EJ, et al.Transfer of metformin
into human milk. Clin Pharmacol Ther. 2003;73:71-77.
84. Briggs GG,Ambrose PJ, Nageotte MP, et al. Excretion of metformin
into breast milk and the effect on nursing infants. Obstet
Gynecol. 2005;105:1437-1441.
85. Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin
into human milk. Diabetologia. 2002;45:1509-1514.
86. Feig DS, Briggs GG, Kraemer JM, et al.Transfer of glyburide
and glipizide into breast milk. Diabetes Care. 2005;28:1851-
1855.
87. Umpierrez GE, Latif KA, Murphy MB, et al.Thyroid dysfunc-
S177
DIABETES IN SPECIAL POPULATIONS